Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly

By Jacob Gronholt-Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.S. peer Eli Lilly and copycat rivals. Novo's shares whipsawed through the day, sliding and then rising on a better-than-expected Medicare pricing deal in the U.S., before eventually falling back as its new CEO struggled to win investors over to ...